Teva Pharma (TEVA) Sees Weaker FY12 Sales, EPS

On its conference call today, Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) provided its current outlook for non-GAAP financial performance for the full year ending December 31, 2012. This outlook is summarized below.

Total net sales of approximately $20-$21 billion, consisting of total U.S. net sales of $10.5 billion, total European net sales of $5.8 billion, and total ROW net sales of $4.2 billion. The Street sees sales of $21.3 billion. These figures include the following major business lines:

• Generic product (including API) net sales of approximately $10.7 billion, consisting of U.S. generic sales of $4.6 billion, European generic sales of $3.4 billion, and ROW generic sales of $2.7 billion.
  
  
• Brand product net sales of approximately $8.0 billion including estimated global net sales of the following products:
  
  
• COPAXONE of $3.8 billion-- TREANDA® of $580 million-- Women’s Health products of $500 million-- ProAir® HFA of $430 million-- QVAR® of $350 million-- PROVIGIL® of $420 million-- AZILECT® of $340 million-- NUVIGIL® of $300 million
  
  
• OTC net sales of approximately $1 billion
  
  
• Other net sales, mostly distribution of third party products, of approximately $800 million.
  
  
• Non-GAAP EPSof $5.30 to $5.40, versus the Street's $5.59.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Airbus revenue rises, delivers 142 commercial aircraft in Q1
• Allison Transmission (ALSN) Tops Q1 EPS by 2c, provides guidance
• T-Mobile posts mixed Q1 top and bottom line, expects more subscribers in 2024